Clinical trial · Observational
Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis
Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ocular muscle myasthenia gravis (Ocular Myasthenia Gravis, OMG) has a high incidence and is difficult to diagnose. It is very necessary to find specific diagnostic indicators for OMG. By collecting peripheral blood of OMG, systemic myasthenia gravis and healthy people, extract miRNAs derived from exosomes in the serum and perform high-throughput sequencing, then use bioinformatics analysis methods to screen specifically expressed miRNAs as biomarkers for OMG diagnosis .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Body fluid diagnosis | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Ocular myasthenia gravis group
- description
- Ocular myasthenia gravis,age between 18-50 years old
- interventionNames
- Device: Body fluid diagnosis
- label
- General myasthenia gravis group
- description
- General myasthenia gravis,age between 18-50 years old
- interventionNames
- Device: Body fluid diagnosis
- label
- Healthy control group
- description
- people who are healthy without any systemic diseases，18-50 years old
- interventionNames
- Device: Body fluid diagnosis
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical manifestations: fluctuating myasthenia; * neostigmine test positive; ③ AChR-Ab, Musk-Ab, LRP4-Ab antibodies positive; ④repetitive nerve stimulation or single fiber EMG Positive (comply with the first one of the above diagnostic criteria and any one of the other three, and at the same time exclude ophthalmoplegia caused by other diseases, the diagnosis can be confirmed). Exclusion Criteria: ①Combined with other autoimmune diseases or other inflammatory diseases; ②Patients with tumorous diseases; * Received targeted biologics, intravenous gamma globulin, plasma exchange therapy within three months before treatment; ④Pregnancy Status or lactation
References
Publications (0)
Data not yet available